Efficacy and tolerability of PCSK9 inhibitors in real-world clinical practice

Keyphrases

• Tolerability 100%
• Real-world Clinical Practice 100%
• Proprotein Convertase Subtilisin/kexin Type 9 Inhibitors 100%
• Scotland 50%
• Health Board 50%
• Statins 50%
• Cardiovascular Mortality 50%
• Cardiovascular Morbidity 50%
• Routine Care 50%
• Hypercholesterolemia 50%
• High Cardiovascular Risk 50%
• Lipid-lowering Therapy 50%
• Homozygous Familial Hypercholesterolemia (HoFH) 50%
• Alirocumab 50%
• Real-world Effectiveness 50%
• Evolocumab 50%

Pharmacology, Toxicology and Pharmaceutical Science

• Tolerability 100%
• Proprotein Convertase 9 100%
• Hydroxymethylglutaryl Coenzyme A Reductase Inhibitor 50%
• Cardiovascular Risk 50%
• Cardiovascular Mortality 50%
• Hypercholesterolemia 50%
• Alirocumab 50%
• Familial Hypercholesterolemia 50%
• Evolocumab 50%